ProAlgaZyme Novel Algae Infusion: Applications in Metabolic Syndrome

• Status: Completed
• Trial end date: 2006-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the effects of supplementation with ProAlgaZyme (a novel fermentation product of a freshwater algae ecosystem) vs. placebo on Metabolic Syndrome and indicators of cardiovascular health including: body weight and fat, blood lipids, inflammatory markers such as hsCRP, blood pressure and fasting blood glucose.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Health Enhancement Products, Inc.
• Collaborator: University of Yaounde

Criteria

Inclusion Criteria:

• Participants must meet 3 of the following criteria:

• BMI ≥30 kg/m2

• HDL Cholesterol of <40

• Triglycerides >150 mg/dl

• Fasting blood glucose >100 mg/dl

• Blood pressure >130/85 mm Hg

• Total Cholesterol of >200 mg/dl

• LDL Cholesterol of >160 mg/dl

• Interleukin 6 (IL-6) >5pg/mL

Exclusion Criteria:

• Morbidly obese: BMI >40 kg/m2

• Taking any cholesterol-lowering medications 30 days prior to the start of enrollment and during the course of the study.

• Enrolled in another clinical study in the past 6 months.

• Pregnant, actively infected, on medication that interfered with healing (for example, steroids), were inflicted with systemic disease such as AIDS, HIV, active hepatitis or active malignancy (clinical signs within the past 5 years), or suffered from diabetes mellitus requiring daily insulin management.